risdiplam
risdiplam: developed by 1 company · 2 clinical trials tracked.
risdiplam evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could risdiplam → PTCT affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| PTC THERAPEUTICS, INC. (PTCT) Spinal muscular atrophy (SMA) | Approved |
Clinical Trials (2)
A Phase 2, Double-Blind Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Apitegromab in Subjects <2 Years Old With Spinal Muscular Atrophy (SMA)
Primary endpoint: Evaluate the PK of apitegromab in subjects <2 years old with SMA
A Phase II, Open-label Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy
Primary endpoint: Plasma Concentrations of Risdiplam
Frequently asked questions
Who is developing risdiplam?
risdiplam is being developed by PTC THERAPEUTICS, INC..
How many clinical trials involve risdiplam?
BioSniper tracks 2 clinical trials involving risdiplam.